Fibroscan Hepatic Fibrosis Screening to Power Patient Motivation, Quality and Prestige in Your Practice Fibroscan is Always Zero Out-of-Pocket Cost for Commercial Insurance 140 covered by Medicare The American Diabetes Association says
"Fibroscan Hepatic Fibrosis Screening to Power" is the property of its rightful owner. Permission is granted to
download and print the materials on this website for personal, non-commercial use only, and to display it
on your personal computer provided you do not modify the materials and that you retain all copyright
notices contained in the materials. By downloading content from our website, you accept the terms of this
agreement.
Presentation Transcript
01
Fibroscan Hepatic Fibrosis Screening to Power Patient Motivation, Quality and Prestige in Your Practice Fibroscan is Always Zero Out-of-Pocket Cost for Commercial Insurance $140 covered by Medicare<br>
02
The American Diabetes Association says that the time is now to screen for metabolic dysfunction-associated statohepatitis (MASH)-related liver fibrosis<br>
03
I was the first primary care physician in California to treat liver fibrosis with the first approved medication, Rezdiffra, in 2024.
Significant difficulties referring patients to Stanford, the only source of Fibroscan testing in our area, resulting in risks to my patients, forced me to start in-office Fibroscan testing.
I am one of the first primary care in the Bay Area to offer in-office Fibroscan testing. (Gastroenterolotists commonly do not purchase Fibroscan machines.)
I met in my office with Dr. Naim Alkhouri a world authority who has published 160 papers on liver fibrosis, to discuss my questions about details in several fibrosis publications, gaining further insights into interpreting Fibroscan results and treating fibrosis.<br>
04
Hepatic fibrosis, essentially inflammation of the liver, is a dangerous and un-addressed disease. Which increases the risk of heart attack, liver cancer and cirrhosis which may require a liver transplant.
Liver fibrosis is the latest major independent risk factor for heart attack. Currently more US women are undergoing liver transplant for MASH-related cirrhosis than alcohol-related cirrhosis. Men are soon to follow.
By 2050 there won’t be enough donor livers or transplant hospitals.<br>
05
Fatty liver (now “liver steatosis”) which is the cause of the dangerous hepatic fibrosis, and fibrosis are common Steatosis is found in 25 to 30% of the general population, 33% of South Asians and 70% of diabetics and 65% (class 1 and 2) to 85% (class 3) of obese patients.
Hepatic fibrosis, the presence of inflammation, is present in 7% of the US population.<br>
06
Fibroscan is the most highly recommended and definitive test for liver steatosis and fibrosis, having replaced biopsy. AASLD, EASL, AGA, ADA guidelines support Fibroscan testing in primary care.
The clinical performance of FibroScan® is supported by more than 100 meta-analyses and over 5,300 peer-reviewed publications.
Standard liver ultrasound is not recommended and is so inaccurate for diagnosis that one Stanford researcher doesn’t even look at the images. Fibroscan is always zero out-of-pocket cost with commercial insurance due to universal coverage and foundation support for deductible costs.
Medicare covered, maximum deductible cost $140.<br>
07
Referring patients to Dr. Sims for the Fibroscan liver ultrasound brings you these benefits: Increase your prestige in the eyes of your patients seeing you as knowledgeable in an emergent disease.
Increase patient motivation to address diabetes and prediabetes, obesity and excess alcohol use, the major risk factors for steatosis and fibrosis. Every day I see patients who have decreased sugar and refined starch intake, quit alcohol and immediately lost weight without weight loss medications on seeing their hepatic steatosis or fibrosis testing result.
Rezdiffra/resmetirom and Wegovy/semaglutide are approved to treat liver fibrosis. 15% of placebo patients achieved a reduction in fibrosis by 1+ stage, which is due to attention to lifestyle. We will usually recheck the Fibroscan after 6 months of your patient lifestyle improvement efforts before starting medication.
Zepbound and Invokana/cangliflozin have comparable data. Referral BENEFITS<br>
08
Referring patients to Dr. Sims for the Fibroscan liver ultrasound brings you these benefits: Follow current guidelines (ADA 2025 “The time is now”) to screen using specifically the Fibroscan machine for hepatic steatosis and fibrosis for patients meeting the FIB-4 cutoff of 1.3 with diabetes, prediabetes or abnormal liver imaging ("fatty liver") or two other risk factors.
These risk factors include obesity, high LDL, low HDL, high TG, elevated ALT or AST, HTN > 130/85, alcohol > 2/day male or > 1.5/day female, smoking or PCOS.
Tell patients the ultrasound procedure uses harmless sound waves with a light tapping sensation on the right side of their chest for 10 to 15 minutes.
Patient preparation requires no food or fluids for 3 hours before the procedure. Referral BENEFITS<br>
09
Referring patients to Dr. Sims for the Fibroscan liver ultrasound brings you these benefits: Avoid the $100+K cost of purchasing your own Fibroscan machine
Dr. Sims’ Fibroscan machine is generations more advanced in accuracy and operator independence than the Stanford unit.
Uses pulsed sound waves to measure the speed and dispersion of the propagation wave through the liver to measure steatosis and fibrosis. Referral BENEFITS<br>
10
FIB-4 is the most sensitive, specific and rapid initial screening to identify those needing Fibroscan testing, using only the ALT, AST, platelet count and age. Most patients meeting the FIB-4 cutoff of 1.3+ have a normal ALT and AST, but FIB-4 correlates most highly with future bleeding varices, hepatic encephalopathy and other liver disease outcomes.
I worked with Epic informatics to make the $4 FIB-4 calculation orderable in Epic to avoid the tedious staff task of entering the ALT, AST, platelet count and age into the UpToDate or MD Calc calculator. The platelet count is added if no CBC is ordered.
You can add FIB-4 to your annual labs.<br>
11
Easy REFERRAL PROCESS Email your request for a Patient Referral Form to Provider.Fibroscan.DrSims@Gmail.com.
Print that form or electronically fill in brief patient clinical data, name and DOB and email fax it to 650-386-0468 and we will find them in Epic and do the rest. If your patient is not in Epic please send a face sheet with insurance.
You’ll receive the date of the already-completed required results discussion visit to view in Epic. The Fibroscan images will be in Media. If you are not on Epic we will send you the results discussion note and test images.
You take over all follow-up care other than Fibroscan rechecks recommended every 6 months to 5 years, depending on Fibroscan results and the presence of risk factors, with a results discussion visit with Dr. Sims' team after each Fibroscan.
If you determine that Rezdiffra is the preferred treatment (no uncontrolled diabetes, weight loss need or renal disease is present to prioritize Wegovy or SGLT2) and prefer Dr. Sims treat, I will do that. Rezdiffra insurance coverage is more complicated and lab monitoring protocols just changed.<br>
12
In summary, these are the benefits to you in referring your patients for Fibroscan: Identify hepatic steatosis and fibrosis disease, and treat to resolution.
Increase patient motivation to address diabetes and prediabetes, obesity, cholesterol, hypertension, alcohol. Increase achievement of goal A1c, weight, cholesterol and blood pressure.
Increase your prestige in the eyes of your patients seeing you as knowledgeable in an emergent disease.<br>